LianBio
NASDAQ Global MarketTotal Valuation
LianBio carries a market capitalization of 34.47M, placing it among publicly traded companies globally. Its enterprise value stands at -55.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 34.47M |
| Enterprise Value | -55.57M |
Share Statistics
LianBio currently has 107.17M shares outstanding.
| Shares Outstanding | 107.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.30 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | -1.93 |
| P/OCF Ratio | -1.92 |
Financial Position
LianBio maintains a current ratio of 10.06, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.06 |
| Quick Ratio | 9.91 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -28.62 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 874,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
LianBio's stock has declined approximately -5.34125% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.34125% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.28 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -105.26M, while operating income came in at -106.56M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -106.56M |
| Pretax Income | -87.11M |
| Net Income | -87.98M |
| EBITDA | -105.26M |
| EBIT | -106.56M |
| Earnings Per Share (EPS) | -0.82 |
Balance Sheet
LianBio holds 252.22M in cash and equivalents against 2.84M in total debt, resulting in a net debt position of -103.46M. Total book value stands at -540.23M, with working capital of 232.18M providing operational flexibility.
| Cash & Cash Equivalents | 252.22M |
| Total Debt | 2.84M |
| Net Debt | -103.46M |
| Equity (Book Value) | -540.23M |
| Book Value Per Share | -5.03 |
| Working Capital | 232.18M |
Cash Flow
LianBio produced -83.53M in operating cash flow over the past twelve months. After subtracting -464,000.00 in capital expenditures, free cash flow totaled -83.99M - equivalent to -0.78 per share.
| Operating Cash Flow | -83.53M |
| Capital Expenditures | -464,000.00 |
| Free Cash Flow | -83.99M |
| FCF Per Share | -0.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -51.90 |
Scores
LianBio posts an Altman Z-Score of 0.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.43 |